More about xbiotech...
The Company is headquartered in a 30,000 square foot facility in Austin, Texas. The Austin facility incorporates all critical operations including discovery, R&D, cGMP manufacturing, drug testing, product formulation and clinical-regulatory affairs. In an era of virtual operations and outsourcing, the Company maintains that bringing together all critical drug development and commercialization activity under one roof is essential to rapid asset growth and risk mitigation: “The first step to successful commercialization is to establish an organization that, in every crucial area of operations, management is connected to both the vision and the product under development; and the desire to succeed must remain palpable at all levels.” JS
The History and direction of xbiotech...
XBiotech was founded based on the understanding that monoclonal antibodies were present in humans that could be cloned and used as therapeutics. The potential resource of using human-sourced antibodies was further recognized as an almost completely overlooked and extraordinary opportunity. XBiotech determined that given the appropriate effort, identifying and developing these true human antibodies would provide for a compelling drug development platform for next generation antibody therapeutics.
In 2005, XBiotech assembled the core technology and expertise to source human antibodies and to establish a discovery program. This gave rise to a unique discovery program for true (natural) human monoclonal antibodies (NATHMAB™). The Company has now learned a great deal about sourcing NATHMAB™ candidates from humans and is aggressively working towards building a pipeline of therapeutic antibodies.
As of 2009, XBiotech has delivered significant value growth based on maturation of its program to develop its lead product candidate. The Company’s lead product candidate is intended to block inflammatory processes involved in progression of many important diseases. The Company plans to launch its clinical program with this candidate therapeutic during the 4th Quarter of 2009.